FDA approves Breyanzi for relapsed, refractory marginal zone lymphoma
The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatment or relapsed after two or more prior ...
Dec 15, 2025
0
0









